Kang Y James
University of Louisville School of Medicine, 511 S. Floyd St., MDR530, Louisville, KY 40202, USA.
Cardiovasc Toxicol. 2007;7(2):95-100. doi: 10.1007/s12012-007-0007-3.
Anthracycline cardiotoxicity is related to oxidative stress generated from the metabolism of anthracyclines in the heart. Studies using transgenic mice with high levels of antioxidants such as catalase or metallothionein (MT) specifically in the heart have demonstrated that elevation of cardiac antioxidant defense leads to intervention of anthracycline cardiotoxicity. MT protection against anthracycline-induced cardiac toxicity is related to its anti-apoptotic effect by inhibiting both p38-MAPK-mediated and mitochondrial cytochrome c-release-mediated apoptotic signaling. The anti-apoptotic effect of MT is closely related to its antioxidant action, which involves regulation of zinc homeostasis by the MT redox cycle. MT interferes with oxidant-mediated detrimental process through at least in part zinc release and zinc transfers directly from MT to acceptor proteins. In addition, MT posttranslationally modulates critical proteins involved in mitochondrial respiration and energy metabolism. All of these processes constitute the mechanisms by which MT protects from anthracycline cardiotoxicity.
蒽环类药物心脏毒性与心脏中蒽环类药物代谢产生的氧化应激有关。使用心脏中特异性表达过氧化氢酶或金属硫蛋白(MT)等高抗氧化剂水平的转基因小鼠进行的研究表明,心脏抗氧化防御能力的提高可导致蒽环类药物心脏毒性的干预。MT对蒽环类药物诱导的心脏毒性的保护作用与其通过抑制p38-MAPK介导的和线粒体细胞色素c释放介导的凋亡信号传导的抗凋亡作用有关。MT的抗凋亡作用与其抗氧化作用密切相关,后者涉及通过MT氧化还原循环调节锌稳态。MT至少部分地通过锌释放以及锌直接从MT转移至受体蛋白来干扰氧化剂介导的有害过程。此外,MT在翻译后调节参与线粒体呼吸和能量代谢的关键蛋白。所有这些过程构成了MT保护免受蒽环类药物心脏毒性的机制。